Noven To Present at UBS Global Generic and Specialty Pharmaceuticals Conference

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that Robert C. Strauss, its President, CEO & Chairman, is scheduled to provide an update on Noven’s business and prospects at the UBS Global Generic and Specialty Pharmaceuticals Conference in New York City on Wednesday, May 9, 2007, at 9:30 a.m. Eastern Time. The public is invited to listen to the presentation live via webcast at www.noven.com, and a replay will be available for at least two weeks at the same site.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven’s prescription patches are approved in over 30 countries and include Vivelle-Dot® (the most prescribed estrogen patch in the U.S.) and Daytrana™ (the first and only patch approved for the treatment of ADHD). Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See www.noven.com for additional information.

Contact:
Alina Bowman
Investor Relations Coordinator
305-253-1916